Table 1 SNPs related to BMI, chromosomal location, name of gene, allele, effect of that SNP and other associated traits

rs2229616

18q21.3

MC4R

C > T

Decreased glycosylated hemoglobin, increased HDL cholesterol

0.020

Decreased waist circumference, decreased blood sugar levels, increased in good cholesterol levels

7888

[22]

rs1121980

16q12.2

FTO

G > A

G > C

Increasing BMI

1.13 × 10^–7

WC

20,374

[23, 24]

rs17782313

18

MC4R

T > A

T > C

High BMI

< 0.05

BP, T2D

216

[25,26,27]

rs7359397

16p11.2

SH2B1

C > A

C > T

Increased BMI

1.88 × 10^–20

Schizophrenia intelligence, self-reported education attainment

249,796

GWAS

[26]

rs13107325

4p24

SLC39A8

C > A

C > T

Increased BMI

1.50 × 10^–13

BP

249,796

GWAS

[26]

rs5443

12p13

GNB3

C > T

Enhanced G-protein activation

0.00002

Obesity, diabetes

Candidate

[28]

rs10767664

11p14.1

BDNF

T > A

T > G

neuronal regulators of appetite or energy balance, increased BMI

4.69 × 10^–26

Coronary artery disease (CAD), allergy/asthma

249,796

GWAS

[26]

rs174575

11q12.2

FADS2

C > G

0.018

1037

[29]

rs5068

1p36.22

NPPA

A > G, T

Low BP

4 × 10^–5

BMI, metabolic syndrome

Candidate

[30, 31]

rs1535

11q12.2

FADS2

A > G

A > T

Decline ability to elongate and desaturate fatty acid

BMI

1037

[29, 32]

rs17700633

18q21.3

MC4R

G > A

increased BMI

0.01

T2D

14,940

[33]

rs1299548

7p21.3

Near C1GALT1

G > A

G > C

Visceral adipose tissue, BMI

0.039

VAT

2513

GWAS

[34]

rs12517906

5q35.3

LOC1002899003/MGAT1

C > A

C > T

Fat absorption

7.3 × 10^–8/6 × 10^–6

Weight

7373

GWAS

[35]

rs7759938

6q16.3

LIN28B

C > A

C > G

C > T

Sex-specific height-growth-regulating effects

5 × 10^–11

Influencing age at menarche/epithelial ovarian cancer

8903

GWAS

[36]

rs9939609

16q12.2

FTO

T > A

Increasing BMI

2 × 10^–7

T2D obesity, high BP

38,759

GWAS

[37]

rs4285184

5q35.3

MGAT1

A > G

Affect the levels of serum unsaturated fatty acid

0.001

Obesity

1152/1076/2249

GWAS

[38]

rs1021001

5q35.3

MGAT1

C > G

Affect the level of serum unsaturated fatty acid

0.003

Obesity

1152/1076/2249

GWAS

[38]

rs939584

2p25.3

TMEM18

C > G

C > T

BMI at 20 years

2.03 × 10^–5

11,586

GWAS

[39]

rs662799

11q23.3

APOA5

G > A

G > C

Higher fasting triglyceride levels

2 × 10^–71

HDL cholesterol, myocardial infarction

2280

[40]

rs13021737

2p25.3

TMEM18

A > C

A > G

A > T

Increased BMI

0.018

Obesity

17,037

[41]

rs1558902

16q12.2

FTO

T > A

Maximum BMI

0.037

T2D, WC, obesity

1450

[42]

rs11030100

11p14.1

BDNF

G > A

G > T

1 × 10^–28

Postpartum depression

173,430

GWAS

[39]

rs1421085

16q12.2

FTO

T > C

Decreased mitochondrial energy generation and increased triglyceride accumulation

6 × 10^–39

T2D

[43]

rs11191580

10q24.33

NT5C2

T > C

Increased BMI

3.83 × 10^–8

Schizophrenia bipolar disorder major depression

86,757/7488–47,354

[44]

rs2535633

3p21.1

ITIH4ITIH4-AS1

1.77 × 10^–10

86,757/7488–47,354

[44]

rs8050136

16q12.2

FTO

C > A

Increased BMI

4 × 10^–8

T2D

4189

[45]

rs12374818

7p

Near BBS9 and VAT

1.1 × 10^–7

2513

GWAS

[34]

rs3751812

16q12.2

FTO

G > T

Increased BMI

6 × 10^–108

GWAS

[46]

rs17817449

16q12.2

FTO

T > A, T > G

Increased BMI

6 × 10^–108

GWAS

[21, 46]

rs10506943

12

CYCSP30 and VAT-BMI

T > C

VAT-BMI

2.42 × 10^–7

2513

[34]

rs12186500

5q35.3

MGAT1

A > G

Ý-Linolenic acid, arachidonic acid, delta 6 and 9 desaturase

0.017

1152/1076/2249

GWAS

[38]

rs143665886

7q31.2

LINC01392

T > C

< 0.0001

Diabetes hypertension

3922

GWAS

[47]

rs11642015

16q12.2

FTO

C > T

High BMI

0.001

Diabetes obesity

1536

GWAS

[48]

rs11583200

1p33

ELAVL4

C > T

Effect positive direction with BMI

0.008

17,037

[41]

rs16858082

4p12

GNPDA2

Leptin level elevate

3 × 10^–4

WC, percent body fat and upper arm circumference

3506

GWAS

[49]

rs12229654

12q24.11

CUX2

T > G

4.56 × 10^–9

Myocardial infarction, high-density lipoprotein cholesterol levels

86,757/7488–47,352

[44]

rs2383207

9p21.3

CDKN2B-AS1

A/G

Increased fasting glucose level

0.001

Weight gain

350

RT-PCR

[50]

rs10146997

14q31.1

NRXN3

A > G

0.0028

T2D WC

7225

[51]

rs261967

5q15

Near PCSK1

A > C

Deregulation lipid metabolism Pancreatic dysfunction

8 × 10^–13

Obesity T2D appendicular lean mass

2215

GWAS

[52]

rs4776970

15q23

MAP2K5

A > C

A > G

A > T

3 × 10^–7

WC, T2D, depressive disorder, schizophrenia, bipolar disorder

1624

[53]

rs10913469

1q25.2

CRYZL2P-SEC16B

T > C

0.0041

WC

7225

GWAS

[51]

rs10938397

4p12

GNPDA2

A > G

increased BMI

0.00093

DBP, WC, waist-to-height ratio and fat mass percentage

3077/3,503

GWAS

[54]

rs6548238

2p25.3

TMEM18

T > C/T > G

Increased BMI

1 × 10^–18

45,069

[55]

rs12597579

16p12.3

SNRPEP3

C/A/T

1 × 10^–8

2813

TaqMan 5′exonuclease allelic discrimination assay

[56]

rs11142387

9q21.12

KLF9

A > T

A > C

Higher BMI

3.4 × 10^–4

Psychiatric disease, memory, performance

62,245/1624

GWAS

[57]

rs13130484

4p12

GNPDA2

C > T

C > A

Higher BMI

3.4 × 10^–4

8914

[58]

rs4680

22q11.21

COMT

G > A

Transfers methyl group to catecholamines, to inactivate

< 0.01

Weight gain/decreased SBP

165/6969

[59,60,61]

rs2206734

6p22.3

CDKAL1

C > G/C > T

Decreasing BMI

1.4 × 10^–11

T2D

62,245

GWAS

[57]

rs7138803

12q13.12

FAIM2

G > T/G > A

Increased BMI

0.015

WC, obesity. DBP

3077/249796

[54, 62]

rs987237

6p12.3

TFAP2B

A > G

Increased BMI

< 5 × 10^–8

Obesity

249,796

GWAS

[62]

rs2241423

15q23

MAP2K5

G > A

Increased BMI

0.029

obesity

474/519/2308

TaqMan polymorphism assay

[63]

rs206936

6p21.31

NUDT3

A > G

Increased BMI

5.3 × 10^–5

1424

GWAS

[64]

rs1514175

1p31.1

TNNI3K

C > T

Increased BMI

5.54 × 10^–5

7225

[51]

rs653178

12

ATXN2

C > G

C > T

High BMI

5 × 10^–7

DBP

GWAS

[56]

rs12411886

10q24.32

CNNM2Intron variant

C/A

High BMI

4 × 10⁵

CAD

GWAS

[17]

rs198358

1p36.22

NPPA-A1

T > C

BMI hypotension

2 × 10^–4

Hypotension

1507

Candidate

[65, 31]

rs794356

7

HIP1

G > A

High BMI

1 × 10^–5

Insomnia

[17]

rs11672660

19q13.32

GIPR

C > T

High BMI

1.64 × 10^–4

T2D, glucose hemostasis

[20]

rs2820436

1q41

LYPLAL1

A/C

High BMI

< 3.79 × 10^–8

102,514

PAGE

[19]

rs10930502

2q31.1

METAP1D

A/G

High BMI

< 2.5 × 10^–7

102,514

PAGE

[19]

rs1934100

9p21.3

ELAVL2

A/T

High BMI

< 5 × 10^–8

200,452

GWAS

[19]

rs754635

3p22.1

CCK

G/C

High BMI

< 5 × 10^–8

200,452

GWAS

[19]

rs7176527

15q25.2

ZSCAN2

C/T

BMI-adjusted WC

< 5 × 10^–8

WC

200,452

GWAS

[19]

rs1720825

3q22.3

MRAS

A/G

4 × 10^–6

CAD

200,452

[19]

rs671

12q24.12

ALDH2

G > A

Increased BMI

3.4 × 10^–11

Hypertension

757/7488–47,352.4204–5435

GWAS

[44, 66]

rs4771122

13q12.2

MTIF3

G > A

G > C

G > T

Increased BMI

< 5 × 10^–8

Obesity

249,796

[62]

rs6265

11p14.1

BNDF

C > T

1 × 10^–14

Obesity hypertension short-term plasticity and learning

3503

GWAS

[39]